Healthcare Industry News: blood collection
News Release - March 14, 2006
Vyteris Regains Rights to LidoSite(R) (ACTYVE Technology)(1) for U.S. Physician Offices SalesFAIR LAWN, N.J.--(HSMN NewsFeed)--March 14, 2006--Vyteris Holdings (Nevada), Inc. (OTCBB:VYHN ) today announced that it has regained the U.S. rights to LidoSite®, an active transdermal analgesic, from B. Braun for sale into physicians' offices. There are more than 500,000 AMA office-based physicians in the U.S. As announced previously, B. Braun commenced its national product launch of LidoSite® into 5,000 U.S. hospitals.
"Regaining rights to the U.S. physician office market for ACTYVE Technology(2) is a significant first step in our focused efforts to create immediate commercialization of our Vyteris assets," said Timothy J. McIntyre, chief executive officer of Vyteris. "Next, we intend to pursue co-marketing/sales partnerships with several large pharmaceutical companies with a significant clinical and market presence in fertile specialty sub-markets. As an example, rheumatoid arthritis patients who have been prescribed TNF Inhibitors, i.e. Enbrel®, may need 1-2 injections per week. Another attractive market, blood collection and clinical testing, represents over 500,000 venipuncture procedures every day. Many of those procedures are conducted in the physician's office. ACTYVE Technology(2) is an ideal solution to alleviating the pain these patients suffer."
Mr. McIntyre continued, "Pediatrics is another market we plan to address, given the need to ease the pain felt by children from needle sticks. In addition, ACTYVE Technology(2) can be the standard of care for treating pain associated with laser ablation of superficial skin during procedures performed by dermatologists. We are very excited to play a part in improving the quality of care for patients and their physicians who no longer need to accept pain as a necessary evil when undergoing medical treatment involving needles or catheters."
In addition to regaining the U.S. rights to LidoSite® for sale into physicians' offices, Vyteris also regained the rights to LidoSite® for sale into the Japanese market.
About Vyteris, Inc.
Vyteris Holdings (Nevada), Inc. developed the first electronically controlled transdermal delivery system to comfortably deliver drugs through the skin without needles.
This technology offers unparalleled control in the rate, dosage and pattern of therapeutic delivery. The Actyve(TM) platform can be applied to a broad range of pharmaceuticals to provide substantial improvements in therapy for FDA approved drugs that are currently delivered orally, by injection or infusion. Vyteris utilizes its commercialization expertise, proven regulatory, manufacturing and product development capabilities to create high-value therapies in partnerships with major healthcare corporations. For more information visit www.vyteris.com.
LidoSite® is a trademark of B. Braun Medical, Inc.
Actyve(TM) is a trademark of Vyteris Holdings (Nevada), Inc.
Statements in this press release other than historical statements constitute "forward-looking statements". Such forward-looking statements are subject to material risks and uncertainties which could cause the Company's forward-looking statements to be materially inaccurate. The Company has described such risks and uncertainties under the caption "Risk Factors" in various filings made with the SEC, including those contained in the Company's Form 10-Q for the quarter ended September 30, 2005.
(1)LidoSite(TM) is a trademark of B. Braun Medical, Inc. Vyteris may market the product in the office base market under another brand name alternative or negotiate brand rights from B. Braun.
(2)ACTYVE Technology (lidocaine and epinephrine)
Source: Vyteris Holdings
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.